We have the ability to specifically edit a cell surface receptor to completely prevent antibody binding while keeping the receptor fully functional. Instead of removing a target entirely, this type of epitope editing has the potential to allow the shielding of any cell surface receptor, thereby enabling a much broader application of our technology.
- Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform
- Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH
- Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform
- Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline
- Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A
No comments to show.